Overview

Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male Subjects

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

Study to determine the relative bioavailability of 500/200 mg of tipranavir/ritonavir (TPV/r) oral solution compared to 500/200 mg of TPV/r capsules following oral administration and to investigate the relative bioavailability of 500/200 mg of TPV/r oral solution with food versus without food.

Phase:

Phase 1

Details

Lead Sponsor:

Boehringer Ingelheim

Treatments:

Pharmaceutical Solutions
Ritonavir
Tipranavir